

How machine translation fast-tracks pharmacovigilance regulatory reporting without cutting corners

With so little margin for error, pharmacovigilance is an area perfectly placed to reap the benefits of integrating AI-powered machine translation solutions into its workflows.

As the scope of pharmacovigilance rapidly increases, so do the reputational and financial costs of contravening its accompanying regulations. This means the pressure is on life sciences organizations—pharmaceutical companies especially—to ensure their workflows keep pace.

A key area in which this challenge manifests is data and document translations. Already a critical part of pharmacovigilance, the need for faster, highly accurate translations is magnified when you look to scale your operations across geographies, legal jurisdictions, and regulatory bodies.

This is where AI-powered machine translation (MT) holds the potential to prove a transformative tool. It revolutionizes pharmacovigilance efficiency and provides your organization with the capability to massively scale its operations in this space.

The impetus to shift to machine translation

The fact that lives are literally on the line as part of your pharmacovigilance reporting underscores the need for seamless communication across any linguistic barriers that appear. However, traditional, human-based translation methods pose significant challenges to globally minded pharmacovigilance operations:

- They are slow. *Human translators peak at around 3000 words per day*, and while the quality of output is high, this lack of speed does hold the potential to jeopardize timely adverse event reporting (AER), for example.
- They are difficult to scale. Whenever a new language pair is needed for translation—perhaps due to entering a new market—a new translator is needed. Your company will also need to source enough experts in the new language to counter the ~3,000 word per day upper limit.

AI-powered MT removes these obstacles at a stroke. Powered by advanced algorithms and deep learning techniques, it can recognize and store specific pharmaceutical terminology and intricacies. This means it instantly translates safety reports, adverse event data, regulatory documents, and medical literature in huge volumes across many thousands of language combinations.

Add in the strict data security built into certain enterprise-grade—i.e., not free and available online—translation tools, and MT not only expedites the translation process but also ensures consistency, precision, and continual adherence to industry and jurisdiction guidelines through enabling a streamlined reporting process. All are critical factors in your continued ability to safeguard patient welfare and maintain regulatory compliance.

Please note:

Not all enterprise-grade machine translation tools offer the same levels of data security. Some will use your data for their own purposes, while others, like Language Weaver from RWS, do not retain any client data. You should check the security measures of any MT solution you are considering to ensure that they align with your expectations and requirements.

Does this mean the end of human translators in pharmacovigilance?

In short, no. MT is not a wholesale replacement of human translators and you should not think of it as such. It is more accurate to describe it as a tool that assists in the speed of translation, helping to significantly speed up and scale your pharmacovigilance operations. Human review and validation will always form a key part of educating any AI-powered MT, as it is through this method that MT learns the intricacies of pharmacovigilance language quickest. It is also often necessary to have a human review to maintain compliance with regulatory standards.

Language Weaver is a leading MT solution that can deliver a huge improvement in translation speed and performance across the widest range of geographies and jurisdictions. Secure-by-design, Language Weaver is used by many of the world's top pharmaceutical

companies, providing over 3,000 language combinations and 150+ direct language pairs into their existing workflows and processes without ever compromising patient data security or confidentiality.

As a highly intelligent tool, Language Weaver can learn industry-specific terminology, nuance, and linguistic intricacies with every use. In doing so, it's vocabulary and accuracy is continually improved, further speeding up the speed and quality of your translations. With a translation capacity of 100,000s+ words per minute, it is available in cloud, on-premises, or hybrid deployment models, enabling flexibility to match your needs and specific organizational circumstances. It's an essential tool for any globally minded life sciences organization needing to prove beyond any doubt its continual regulatory adherence.

Discover the potential of implementing Language Weaver across your entire operations, and how it can rapidly accelerate your teams' time to impact by visiting our dedicated landing page.

[languageweaver.com/life-sciences](https://www.languageweaver.com/life-sciences)

About RWS

RWS Holdings plc is a unique, world-leading provider of technology-enabled language, content and intellectual property services. Through content transformation and multilingual data analysis, our combination of AI-enabled technology and human expertise helps our clients to grow by ensuring they are understood anywhere, in any language.

Our purpose is unlocking global understanding. By combining cultural understanding, client understanding and technical understanding, our services and technology assist our clients to acquire and retain customers, deliver engaging user experiences, maintain compliance and gain actionable insights into their data and content.

Over the past 20 years we've been evolving our own AI solutions as well as helping clients to explore, build and use multilingual AI applications. With 45+ AI-related patents and more than 100 peer-reviewed papers, we have the experience and expertise to support clients on their AI journey.

We work with over 80% of the world's top 100 brands, more than three-quarters of Fortune's 20 'Most Admired Companies' and almost all of the top pharmaceutical companies, investment banks, law firms and patent filers. Our client base spans Europe, Asia Pacific, Africa and North and South America. Our 65+ global locations across five continents service clients in the automotive, chemical, financial, legal, medical, pharmaceutical, technology and telecommunications sectors.

Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).

For further information, please visit: www.rws.com

© 2024 All rights reserved. Information contained herein is deemed confidential and the proprietary information of RWS Group*.

*RWS Group shall mean RWS Holdings plc for and on behalf of its affiliates and subsidiaries.

